Drugs / Cagrilintide
Cagrilintide
Trials 46
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 122 trials · 1 met primary | ||||||
| Phase 1 | NCT07607587 | May 2026 → Nov 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07605052 | May → Aug 2026 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT07557953 | Apr 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07527195 | Apr 2026 → Apr 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07411560 | Feb 2026 → Jan 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07010432 | Jun 2025 → May 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06719011 | Dec 2024 → Mar 2026 overdue | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06716307 | Dec 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06403761 | May 2024 → Dec 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06289504 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06207877 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06267092 | Feb 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05804162 | Apr → Aug 2023 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT05564104 | Apr 2023 → Sep 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05254158 | Mar → Sep 2022 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04940078 | Jul 2021 → Jan 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04209049 | Jan 2020 → Jan 2021 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04074174 | Sep 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03787225 | Jan → Jun 2019 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03600480 | Jul 2018 → Jun 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02958085 | Nov 2016 → Jan 2018 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02300844 | Dec 2014 → Mar 2016 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT07357740 | Aug 2026 → Aug 2027 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06409130 | May 2024 → Nov 2025 | alcoholic liver disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06131372 | Apr 2024 → Sep 2025 | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05016882 | Aug 2021 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | Missed primary |
| Phase 2 | NCT04982575 | Aug 2021 → Jul 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 2 | NCT03856047 | Mar 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 318 trials · 4 met primary | ||||||
| Phase 3 | NCT07817251 | Sep 2026 → Jun 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07745504 | Aug 2026 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07357766 | Jun 2026 → Nov 2027 | obesity disorder | Novo Nordisk A/S | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT07564414 | May 2026 → Feb 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07253285 | Jan 2026 → Mar 2030 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07220759 | Nov 2025 → May 2027 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07220642 | Nov 2025 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06780449 | Feb 2025 → Aug 2028 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06534411 | Nov 2024 → Jun 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06388187 | Jun 2024 → Apr 2026 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06221969 | Jan 2024 → Mar 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06131437 | Nov 2023 → Dec 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06065540 | Sep 2023 → Nov 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT05996848 | Aug 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05813925 | Apr 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT05669755 | Mar 2023 → Sep 2027 expected | cardiovascular disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05394519 | Feb 2023 → Jan 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT05567796 | Nov 2022 → Oct 2024 overdue | obesity disorder | Novo Nordisk A/S | Active not recruiting | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06323161 Comparator | Mar 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06323174 Comparator | Mar 2024 → Oct 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Novo Nordisk A/S | Results Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 novonordisk.com ↗
Additionally, CagriSema substantially improved eating behaviour, reduced ‘food noise’, cravings, hunger, appetite, and food-related thoughts and improved craving control after both 22 and 52 weeks of treatment. |
| 2026-09-21 | Novo Nordisk A/S | Results Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial novonordisk.com ↗
In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1%, respectively. |
| 2026-06-07 | Novo Nordisk A/S | Results Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 novonordisk.com ↗
CagriSema, a once-weekly investigational treatment that combines a novel amylin analog with a GLP-1 receptor agonist (RA), achieved significant reductions in HbA1c and bodyweight versus comparators across three phase 3 trials in adults with type 2 diabetes (T2D)1-3 |
| 2026-02-23 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved novonordisk.com ↗
CagriSema achieved 23% weight loss after 84 weeks of treatment |
| 2026-02-02 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial novonordisk.com ↗
Superiority was established on both weight loss and HbA1c versus the individual components. |
| 2025-12-18 | Novo Nordisk A/S | Regulatory Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management novonordisk.com ↗ |
| 2025-11-06 | Novo Nordisk A/S | Results Novo Nordisk's CagriSema associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® novonordisk.com ↗
With CagriSema treatment, systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo).* |
| 2025-03-10 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial novonordisk.com ↗
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. |
| 2024-12-20 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial novonordisk.com ↗
In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo. |
| 2022-08-22 | Novo Nordisk A/S | Results Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes novonordisk.com ↗
After 32 weeks of treatment, people treated with CagriSema achieved a numerically higher HbA1c reduction of 2.18%-points compared to a reduction of 1.79%-points for people treated with semaglutide and 0.93%-points with cagrilintide alone. |
All press releases naming this drug 10 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cagrilintide | “Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor...” PMID 42228334 ↗ Jun 202639“Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes” NCT07817251 ↗ “Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.” NCT07357766 ↗ “Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.” NCT07357740 ↗ “Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.” NCT07564414 ↗ |
| Known as | cagrilintide B | “Participants will receive a single subcutaneous (s.c.) dose of CagriSema (cagrilintide B and semaglutide I) in DV3384 pen-injector in period 1 followed by a single s.c. dose of...” NCT06716307 ↗ |
| Known as | Cagrilintide component of cagrisema | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802169 ↗ |
| Known as | NNC0174-0833 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958085 ↗ |
| Action | Activate | “Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management” PMID 42228334 ↗ Jun 2026 |
| Modality | Peptide | “Cagrilintide, a long-acting amylin analogue” PMID 33894838 ↗ Apr 2021 |
| Modality | Protein / enzyme biologic | — CHEMBL4802169 ↗ |
| Route | Subcutaneous | “single s.c. (subcutaneous/under the skin) dose” NCT02300844 ↗ |